Vir Biotechnology, Inc. (VIR)
Upgrades & Downgrades
Latest VIR news
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
2 February 2023
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg...
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
1 February 2023
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade
24 January 2023
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Stocks That Could Turn $100 Into $1,000 by 2028
22 January 2023
These growth stocks have substantial tailwinds.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
20 January 2023
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
Vir Biotechnology: High Potential Returns With High Volatility Risks
19 January 2023
Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 202...
Vir Biotechnology: The First Entry In My Long Term Value Portfolio
8 January 2023
Today, I explain why I've taken a position in VIR, including going over its pipeline, partners, and anticipated milestones. I then look at the company's valuation and cash position as well as Seeking ...
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
28 December 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Vir Biotechnology: A 'Magic Formula' Top Performer
22 December 2022
Joel Greenblatt (Trades, Portfolio), the manager of Gotham Capital, has what he calls a “Magic Formula” for investing. First detailed in "The Little Book That Beats the Market," this formula is based ...